So lets start with the positives:
- for a change, the presentation actually has some substance & explains what the businesses in Australia & US do
- the turnaround in the US is looking good, but hard to say if this is sustainable
The negatives
- after all that investment, they just exited SEA JV (I assume this is everything in Asia) with a 1 liner in this preso
- how slow is the UK roll out; they have been spending money there since 1H20 (and how transferrable is this app if as it seems based on timeline, it took them 2 years to get it up and running).....and 21k in revenues for FY2021 (what is the point!!)
- Australia pharmacy business needs serious review.....charging $145 per month per pharmacy and they are only raising prices to $159-$179....pharmacies are minting money and this fee just seems ridiculously cheap even after a price rise
- transactional fees are no better at ~$50 per pharmacy per month (it actually dropped in FY2021)......how is that possible with delivery/online payments/online scripts etc.....all this optionality was built and clearly not being used or paying for itself
- I wish they'd drop the ridiculous metrics of 2m patients in Aus/180m in US/66m in UK....etc etc.....all BS. If they had 2m in active patients using the App in Aus, it would be ridiculously embarrassing to understand that works out to $4 per patient in revenues they are earning per year......seriously stop using nonsense metrics. Same goes with using TAM numbers......8bn in US & 300m in UK.....all pure BS
- $30m in revenues in 1H22 is not enough......that is Gross Profit of ~16.5m and expenses are running at ~24.5m....even if you exclude one offs and non cash items you get costs of 20-21m meaning they will burn $3.5-4.5m in 1H22
If they continue with just 30m in revenues, they are likely to burn that 3.4-4.5m in 1H and then need a further ~4m in May for contingent consideration....that means a capital raise in the CY2022 (1st quarter) unless revenues and/or margins improve
I did not manage to dial in to the call, but if anyone did, would appreciate a download of what was discussed (especially around cashflow)
- Forums
- ASX - By Stock
- MDR
- Ann: FY21 Results Presentation
MDR
medadvisor limited
Add to My Watchlist
3.75%
!
7.7¢

Ann: FY21 Results Presentation, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
7.7¢ |
Change
-0.003(3.75%) |
Mkt cap ! $48.14M |
Open | High | Low | Value | Volume |
8.0¢ | 8.0¢ | 7.7¢ | $41.22K | 531.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 56330 | 7.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.0¢ | 41148 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 56330 | 0.076 |
6 | 436732 | 0.075 |
1 | 7045 | 0.071 |
3 | 550857 | 0.070 |
1 | 250000 | 0.065 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 41148 | 2 |
0.081 | 10331 | 1 |
0.082 | 100000 | 1 |
0.084 | 9379 | 1 |
0.086 | 150000 | 1 |
Last trade - 15.44pm 28/07/2025 (20 minute delay) ? |
Featured News
MDR (ASX) Chart |